Home › Premature Birth › NCT06007547

Prophylactic Minimally Invasive Surfactant Evaluation

Who can join

15 Minutes · All sexes · Healthy volunteers welcome

Inclusion Criteria:

* Gestational age \<30 weeks
* Antenatal consent from Parent

Exclusion Criteria:

* Congenital anomalies
* Alternate cause of respiratory distress

About the study

The purpose of this study is to explore the question: Does prophylactic administration of exogenous surfactant in the delivery room, using a minimally-invasive technique, improve outcome in preterm infants 22-29 weeks' gestation compared to rescue treatment using the same technique?

What is being tested

• Poractant Alfa (drug)

Sponsor: Endeavor Health · Participants: 200 · Started: Jan 1, 2024

Contact the study team

• Matthew Derrick, MBBS · Phone: 8475702920

Official record on ClinicalTrials.gov — NCT06007547

Locations in the U.S.

Conditions

• Premature Birth
• Respiratory Distress Syndrome

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.